Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

Share this content:
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.

The albumin-to-fibrinogen ratio (AFR) at diagnosis may be predictive of poor outcomes among patients with untreated chronic lymphocytic leukemia (CLL), according to a study published in Cancer Research and Treatment.1

Low albumin and high fibrinogen are indicators of nutrition and inflammation and have been associated with poor outcomes in various diseases, including CLL. Previous studies have shown that AFR, a novel immune biomarker, may predict poor outcomes in non-small cell cancer but its ability to determine the prognosis of patients with CLL has not been investigated.

For this retrospective study, researchers evaluated the outcomes of 191 patients with treatment-naive CLL. Assessed patients had evaluable laboratory measurements from within 24 hours after first admission, including absolute lymphocyte and platelet counts, hemoglobin, serum albumin, fibrinogen, and mutational status.

The AFR cut-off point was set at 9.7, and the median AFR was 17.19 at diagnosis. Older patients greater than 65 years had a low AFR more commonly compared with younger patients. Overall, 20 patients had low AFR (≤ 9.7) compared with 171 patients who had high AFR (> 9.7).

Results showed that patients with a low AFR had significantly reduced overall survival (OS) compared with patients who had a high AFR (P < .001). The 3-year OS rate was 56.1% and 92.8% in the low and high groups, respectively, and the 5-year OS rate was 56.1% and 82.4%, respectively. No significant differences in treatment-free survival, however, were observed between the 2 groups.

A multivariate analysis revealed that AFR was a significant, negative independent prognostic factor for OS (P = .003), and was associated with worse outcomes regardless of any other adverse prognostic or clinical factors observed in patients.

The authors concluded that “further researches containing a larger population and multicenter data are needed to better understand the roles of AFR level in CLL.”

Reference

  1. Zou YX, Qiao J, Zhu HY, et al. Albumin-to-fibrinogen ratio as an independent prognostic parameter in untreated chronic lymphocytic leukemia: a retrospective study of 191 cases [published online August 1, 2018]. Cancer Res Treat. doi: 10.4143/crt.2018.358 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs